Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
Objective: To compare the durations of response achieved with adjunctive vagus nerve stimulation (VNS + TAU) vs treatment as usual (TAU) alone in treatment-resistant depression (TRD) over a 5-year period in the TRD registry. Materials and methods: Data from 271 participants on TAU and 328 participants on VNS + TAU were analyzed. Response was defined as ≥50% decrease in baseline Montgomery–Åsberg Depression Rating Scale (MADRS) score at postbaseline visit and was considered retained until the decrease was <40%. MADRS was obtained quarterly in year 1 and biannually thereafter. Time-to-events were estimated using Kaplan–Meier method and compared using log-rank test. HR was estimated using Cox proportion hazard model. Results: In the VNS + TAU arm, 62.5% (205/328) of participants had a first response over 5 years compared with 39.9% (108/271) in TAU. The time to first response was significantly shorter for VNS + TAU than for TAU ( P <0.01). For responders in the first year, median time to relapse from first response was 10.1 months (Q1=4.2, Q3=31.5) for VNS + TAU vs 7.3 months (Q1=3.1, Q3=17.6) for TAU ( P <0.01). HR=0.6 (95% CI: 0.4, 0.9) revealed a significantly lower chance for relapse in VNS + TAU. Probability of retaining first response for a year was 0.39 (0.27, 0.51) for TAU and 0.47 (0.38, 0.56) for VNS + TAU. Timing of the onset of the response did not impact the durability of the response. Conclusion: VNS therapy added to TAU in severe TRD leads to rapid onset and higher likelihood of response, and a greater durability of the response as compared to TAU alone. Keywords: depressive disorder, treatment-resistant depression, vagus nerve stimulation, longitudinal study, durability of response
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“Berry et al found that for VNS + TAU, among participants who achieved response at 24 weeks as per the Montgomery–Åsberg Depression Rating Scale (MADRS), 153 (153/217=71%) had a sustained response at 48 weeks.(9,14) Additionally, of the 104 participants in the VNS + TAU group evaluated at 96 weeks, 70 (70/104=67%) had…”
Method(1976) · Medical Entomology and Zoology · Cited by 8,899
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationFrank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 1×
“The second challenge focuses on the maintenance of the optimal symptomatic benefit once achieved in the acute treatment phase, that is, the prevention of relapse (a return of the current episode) or recurrence (onset of a new episode).(3,4) The Sequenced Treatment Alternatives to Achieve Remission in Depression (STAR-…”
BackgroundTRIVEDI, M. H., RUSH, A. J., IBRAHIM, H. M., CARMODY, T. J., BIGGS, M. M., SUPPES, T., CRISMON, M. L., SHORES-WILSON, K., TOPRAC, M. G., DENNEHY, E. B., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291703001107 · Cited by 968
Self-citationRush, A. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.11.1905 · Cited by 870 · cited 3×
“Another benchmark by which to evaluate the present results is the Level 4 STAR-D participants all of whom had failed on three prior well-delivered medication treatments.(1) While the acute trial was only 12 weeks in the fourth step, the remission rate was 15% and the response rate was not much greater.”
BackgroundSelf-citation(1997) · PubMed · Cited by 727
Self-citationReport by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707 · cited 1×
“The second challenge focuses on the maintenance of the optimal symptomatic benefit once achieved in the acute treatment phase, that is, the prevention of relapse (a return of the current episode) or recurrence (onset of a new episode).(3,4) The Sequenced Treatment Alternatives to Achieve Remission in Depression (STAR-…”
BackgroundSelf-citationRush, A. J., George, M. S., Sackeim, H. A., Marangell, L. B., Husain, M. M., Giller, C., Nahas, Z., Haines, S., Simpson, R. K., & Goodman, R. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00304-2 · Cited by 688
Self-citation
Research works printed but not linked: 1
- [7]AHRQ Technology Assessment Program: Definition of Treatment-Resistant Depression in the Medicare Population. Project ID: PSYT0816 Agency for Healthcare Research and Quality. US Department of Health and Human Services 2018 Available from: https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id105TA.pdf Accessed April 18, 2018 30260611
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
McAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.02.023 · Cited by 278
Self-citationBottomley, J., LeReun, C., Diamantopoulos, A., Mitchell, S., & Gaynes, B. N. (2019) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2019.152156 · Cited by 166
Vagus Nerve Stimulation in Rodent Models: An Overview of Technical Considerations
Noller, C. M., Levine, Y. A., Urakov, T. M., Aronson, J. P., & Nash, M. S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00911 · Cited by 70
Neuromodulation Strategies for the Treatment of Depression
Conroy, S. K., & Holtzheimer, P. E. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21101034 · Cited by 68
Vagus nerve stimulation: An update on a novel treatment for treatment-resistant depression
Kamel, L. Y., Xiong, W., Gott, B. M., Kumar, A., & Conway, C. R. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120171 · Cited by 67
Self-citationConway, C. R., Olin, B., Aaronson, S. T., Sackeïm, H. A., Bunker, M. T., Kriedt, C. L., Greco, T., Broglio, K., Vestrucci, M., & Rush, A. J. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106066 · Cited by 42
Self-citationPope, B. S., & Wood, S. K. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.06.031 · Cited by 46
“In male and female patients with treatment-resistant depression, VNS used as an adjuvant to their pharmacological treatment reduced the time to first response and decreased the chance for relapse compared to controls who continued with usual treatment (Kumar et al., 2019).”
BackgroundNeuro-immune interactions: Exploring the anti-inflammatory role of the vagus nerve
Liu, L., Lou, S., Fu, D., Ji, P., Xia, P., Shuang, S., Dong, W., Yuan, X., Wang, J., Xie, K., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114941 · Cited by 49
McAllister-Williams, H., Sousa, S., Kumar, A., Greco, T., Bunker, M. T., Aaronson, S. T., Conway, C. R., & Rush, A. J. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-020-0178-4 · Cited by 34
Self-citationValenza, G. (2023) · Frontiers in Network Physiology · doi:10.3389/fnetp.2023.1125495 · Cited by 38
Fetzer, S., Dibué, M., Nagel, A. M., & Trollmann, R. (2021) · Neuroradiology · doi:10.1007/s00234-021-02705-y · Cited by 29
“2014 [16] n/a de Jonge JC et al; Epilepsia 2014 [17] fMRI and others Rösch J et al.”
BackgroundAaronson, S. T., Goldwaser, E. L., Kutzer, D. J., McAllister-Williams, H., Sackeïm, H. A., & Rush, A. J. (2020) · Journal of Ect · doi:10.1097/yct.0000000000000724 · Cited by 23
“Postimplantation adverse effects were consistent with the previous literature with the most common being a change in vocal quality (in 70%).(1,7,8) No subjects were unable to tolerate adequate stimulation parameters.”
BackgroundResultSelf-citationXie, C., Gao, X., Liu, G., Tang, H., & Li, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1130697 · Cited by 25
“treatment of specific neurological and psychiatric disorders, including epilepsy, cluster headache, and depression (37).”
BackgroundMcAllister-Williams, H., Bulmer, S., Newton, K. S., Heath, K., Cousins, D. A., & Currie, A. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.020 · Cited by 21
Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder
Lee, Y. K., Gold, M. S., & Fuehrlein, B. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120094 · Cited by 21
Sackeim, H. A., Dibué, M., Bunker, M. T., & Rush, A. J. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s286977 · Cited by 15
Self-citationKraus, C., Quach, D., Sholtes, D. M., Kavakbasi, E., De Zwaef, R., Dibué, M., Zajecka, J., & Baune, B. T. (2022) · Neuromodulation: Technology at the Neural Interface · doi:10.1016/j.neurom.2021.12.010 · Cited by 14
Vlaicu, A., & Vlaicu, M. B. ̆. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1779751 · Cited by 12
Sackeïm, H. A., Rush, A. J., Greco, T., Jiang, M., Badejo, S., Bunker, M. T., Aaronson, S. T., Conway, C. R., Demyttenaere, K., Young, A. H., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291722003798 · Cited by 12
“…the durability of improvement is a fundamental consideration, particularly when interventions yield only modest acute gains, are expensive or resource intensive, or when a long period of treatment is required to achieve the benefit (Faxon et al., 2004; Kumar et al., 2019; Shiroma et al., 2020).”
Self-citationSharma, B., Jones, K. A., Lober, R. M., & Hatcher-Solis, C. N. (2025) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2025.1609654 · Cited by 12
Cardiovascular disease and depression: a bidirectional relationship and its clinical implications
Wu, J., Tian, Z., Qi, Z., Liu, X., & Yu, P. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1675680 · Cited by 15
“Research indicates that VNS may be an effective treatment for depressed patients with comorbid CVD. Compared to the control group continuing standard treatment, VNS combined with pharmacotherapy shortens the response time and reduces the risk of depressive relapse (259).”
Adjunctive Vagus Nerve Stimulation for Treatment-Resistant Depression: a Quantitative Analysis
Zhang, X., Qing, M.-J., Rao, Y.-H., & Guo, Y. (2020) · Psychiatric Quarterly · doi:10.1007/s11126-020-09726-5 · Cited by 13
A narrative review on invasive brain stimulation for treatment-resistant depression
Dandekar, M. P., Díaz, A. P., Rahman, Z., da Silva, R. H., Nahas, Z. H., Aaronson, S. T., Selvaraj, S., Fenoy, A. J., Sanches, M., Soares, J. C., et al. (2021) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2021-1874 · Cited by 13
Self-citationTheiss, P., & Slavin, K. V. (2022) · Progress in brain research · doi:10.1016/bs.pbr.2022.01.001 · Cited by 5
Sackeïm, H. A. (2021) · Journal of Ect · doi:10.1097/yct.0000000000000745 · Cited by 6
Selective myelinated nerve fiber stimulation via temporal interfering electric fields
Wang, G., & Dokos, S. (2021) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc46164.2021.9630073 · Cited by 4
“Use of temporal interfering (TI) fields for nerve stimulation (TI), such as vagus nerve stimulation (VNS), have led to widespread excitement about the possible treatment of various neural conditions, including epilepsy, depression and cluster headaches [1-5].”
BackgroundInvasive Neuromodulation Techniques for Treatment-Resistant Depression
Theiss, P., Pucci, F. G., & Slavin, K. V. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_460 · Cited by 4
Vagus Nerve Stimulation for Treatment-Resistant Depression: Current Status of This Novel Treatment
Conway, C. R., Hristidis, V. C., Gott, B. M., & Willie, J. T. (2022) · Psychiatric Annals · doi:10.3928/00485713-20220620-01 · Cited by 2
Self-citationNodoMap: a spatio-cellular map of the mouse nodose gangliaPreprint
Cheng, S., Dowsett, G. K. C., Rainbow, K., Norton, M., Roberts, A. G., Phuah, P., Bewick, G. A., Lam, B., Yeo, G. S. H., & Murphy, K. G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.11.653249 · Cited by 3
Difficult-to-Treat Depression and the Role of Vagus Nerve Stimulation
McAllister-Williams, H., & Costa, T. (2022) · Psychiatric Annals · doi:10.3928/00485713-20220622-01 · Cited by 1
Rafe, M. R., Waris, A., & Saha, P. (2025) · Health Science Reports · doi:10.1002/hsr2.70370 · Cited by 3
Dépression résistante aux traitements
Vlaicu, M. B. ̆., & Vlaicu, A. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-77862-9.00005-0
Yogarajah, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-820480-1.00113-3
Gillespie, C. F., & Nemeroff, C. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00046-7
Challenges in management of treatment-resistant depression
Piech, G. M., & Lis, I. (2024) · Biuletyn Głównej Biblioteki Lekarskiej · doi:10.2478/bgbl-2024-0032
立石, 洋., & 溝口, 義. (2024) · Kyushu Neuropsychiatry · doi:10.11642/kyushuneurop.70.1_3
Shibah, S. R. M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5902903
Advances in the Clinical Application of Neurostimulation in Major Depression
Göke, K., Kaster, T. S., & Blumberger, D. M. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-981-95-6872-7_28
Breit, S. (2026) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20260006
“…on the inflammatory system, acts faster, and has a stronger antidepressant effect, whereas VNS has a slower, more targeted and direct impact on inflammation through the cholinergic anti-inflammatory pathway, inducing a longer-lasting antidepressant effect in patients with TRD [85,111,114–116].”
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890427118.bm02
NodoMap: A single-cell and spatial transcriptomic atlas of the mouse nodose ganglion
Cheng, S., Dowsett, G. K. C., Rainbow, K., Norton, M., Roberts, A. G., Phuah, P., Bewick, G. A., Lam, B., Yeo, G. S. H., & Murphy, K. G. (2026) · Cell Press Blue · doi:10.1016/j.cpblue.2026.100072 · Cited by 1
Conway, C. R., Aaronson, S. T., Rush, A. J., Lee, Y.-C. (., Gordon, C., Shy, O., Bunker, M. T., Riva‐Posse, P., George, M. S., Zajecka, J., et al. (2026) · medRxiv · doi:10.64898/2026.07.31.26358854
Self-citationHasanieh, K. A., Zorumski, C. F., Sackeim, H. A., Bunker, M. T., Aaronson, S. T., Rush, A. J., & Conway, C. R. (2026) · Current Addiction Reports · doi:10.1007/s40429-026-00797-1
“In contrast, no electrical parameter optimization was attempted in either the registry [33, 34] or the European trial [29].”
InfluentialSelf-citation
Metadata
- Authors
- Kumar, A., Bunker, M. T., Aaronson, S. T., Conway, C. R., Rothschild, A. J., Mordenti, G., & Rush, A. J.
- Affiliations
- LivaNova (United States) (US)
- Washington University in St. Louis (US)
- Sheppard and Enoch Pratt Hospital (US)
- University of Massachusetts Chan Medical School (US)
- National University of Singapore (SG)
- Corresponding author
- Kumar, Arun
- ORCID
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2019-02
- Volume
- Volume 15
- Pages
- 457-468
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC6387594
- OpenAlex
- W2912354242
- Cited by
- 44
- References
- 23
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 6 · 2020: 9 · 2019: 2
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, other-oa)
- eScholarship@UMassChan (submittedVersion, cc-by-nc)
- National University of Singapore (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- American Foundation for Suicide Prevention
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- Stanley Medical Research Institute
- Foundation for Barnes-Jewish Hospital
- University of Texas Southwestern Medical Center
- Sunovion
- LivaNova
- Neurocrine Biosciences
- Sage Therapeutics
- Assurex Health
- NeoSync
- National Institutes of Health
- Allergan
- National Institute of Mental Health
- Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine in St. Louis
- Topics
- Life Sciences › Neuroscience › Neurology › Vagus Nerve Stimulation Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- vagus nerve stimulation, treatment-resistant depression, adjunctive therapy, durability of response, relapse, time to response, usual care, severe depression, longitudinal outcomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.